Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Xiaojuan Chen, BsN, MsN, Foong-Gwan Lee, BsN, Shi Hui Clarice Choong, MBBS, MRCP, Xiao-Shi Saw, BSc(Pharm), Lon-Wann Sai, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Hian Li Esther Hian Li Chan, MBBS, MRCP, FRCPATH, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Yen Lin Chee, MBBS, FRCPATH, PhD, Yee Mei Lee, BsN, MsN, PhD

Blood (2019) 134 (Supplement_1): 2152.

https://doi.org/10.1182/blood-2019-129858

Published: 2019

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

CD93-Signaling Regulates Self-Renewal and Proliferation of Chronic Myeloid Leukemia Stem Cells in Mice and Humans and Might be a Promising Target for Treatment

Carsten Riether, PhD, Ramin Radpour, PhD, Chantal L. Bachmann, MSc, Christian M Schürch, MD PhD, Miroslav Arambasic, PhD, Gabriela M Baerlocher, MD, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 187.

https://doi.org/10.1182/blood-2019-127864

Published: 2019

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Blood (2019) 134 (Supplement_1): 5830.

https://doi.org/10.1182/blood-2019-127402

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study

Hua Wang, MD, Yue Lu

Blood (2018) 132 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2018-99-113292

Published: 2018

Journal Articles

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

Karin Melanie Cabanillas Stanchi, MSc, Julia Vek, Dr. MD, Patrick Schlegel, MD, Christian M. Seitz, MD, Joachim Rupprecht, Dr. MD, Sarah Schober, Dr. MD, Sebastian Michaelis, Dr. MD, Carmen Malaval, Dr. MD, Tim Flaadt, Dr. MD, Lukas Schnaufer, Dr. MD, Manon Queudeville, Dr. MD, Judith Feucht, Dr. MD, Peter Lang, MD, Rupert Handgretinger, MD PhD, Michaela Döring, Dr. MD

Blood (2018) 132 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2018-99-112762

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Vittorio Ruggero Zilioli, Periana Minga, Lara Crucitti, Erika Meli, Monica Luigia Torretta, Anna Esposito, Chiara Rusconi, Roberto Cairoli

Blood (2018) 132 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2018-99-116543

Published: 2018

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

Journal Articles

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Semjon Willier, MD, Karin Melanie Cabanillas Stanchi, MSc, Martha von Have, Dr. MD, Vera Binder, Dr. MD, Franziska Blaeschke, Dr. MD, Tobias F. Feuchtinger, Prof. Dr. MD, Michaela Döring, Dr. MD

Blood (2017) 130 (Supplement 1): 3220.

https://doi.org/10.1182/blood.V130.Suppl_1.3220.3220

Published: 2017

Journal Articles

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Michaela Döring, Dr. MD, Karin Melanie Cabanillas Stanchi, MSc, Manon Queudeville, Dr. MD, Ulrike Hartmann, Dr., Michael Ost, Dr. MD, Marie-Sarah Koch, Dr. MD, Carmen Malaval, Dr. MD, Markus Mezger, Dr. MD Dr. rer. nat., Sarah Schober, Dr. MD, Simone Weber, Dr. MD, Veit Lange, Dr. MD, Rupert Handgretinger, MD, Martin Ebinger, MD

Blood (2017) 130 (Supplement 1): 3228.

https://doi.org/10.1182/blood.V130.Suppl_1.3228.3228

Published: 2017

Journal Articles

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Clara Chen, PhD BS, MS, Katherine Byrne, Pam Hallworth, Christopher A. Yasenchak, MD

Blood (2017) 130 (Supplement 1): 5653.

https://doi.org/10.1182/blood.V130.Suppl_1.5653.5653

Published: 2017

Journal Articles

Use of Premedication Prior to Asparaginase (ASNase) Administration in Pediatric Acute Lymphoblastic Leukemia (ALL): Effect on Treatment Completion Rate

Celine Bernard, MBA, Nathan Rustay, PhD, Kira Mamedov, MD

Blood (2017) 130 (Supplement 1): 5574.

https://doi.org/10.1182/blood.V130.Suppl_1.5574.5574

Published: 2017

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation

Alessandra Pompa, Laura Paris, MD, Francesca Guidotti, MD, Valeria Ferla, MD, Monica Galli, MD PhD, Alessandro Rambaldi, MD Prof, Luca Baldini, Agostino Cortelezzi, Prof

Blood (2017) 130 (Supplement 1): 4476.

https://doi.org/10.1182/blood.V130.Suppl_1.4476.4476

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

NARROW

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

CD93-Signaling Regulates Self-Renewal and Proliferation of Chronic Myeloid Leukemia Stem Cells in Mice and Humans and Might be a Promising Target for Treatment

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Use of Premedication Prior to Asparaginase (ASNase) Administration in Pediatric Acute Lymphoblastic Leukemia (ALL): Effect on Treatment Completion Rate

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only